Maintenance therapy with a multi-kinase inhibitor, sorafenib, in patients with FMS-like tyrosine kinase-3-mutated acute myeloid leukemia (AML)22 or low-dose azacitidine in patients with AML and myelodysplastic syndromes34 have shown promising results but require confirmation in large clinical trials. This evidence concerns the gene FLT3 and acute myeloid leukemia.